C. Abraham and J. Cho, Inflammatory Bowel Disease, New England Journal of Medicine, vol.361, issue.21, pp.2066-78, 2009.
DOI : 10.1056/NEJMra0804647

D. Baumgart and W. Sandborn, Crohn's disease. Lancet, Nov, vol.3380, issue.9853, pp.1590-605, 2012.

S. Danese and C. Fiocchi, Ulcerative Colitis, New England Journal of Medicine, vol.365, issue.18, pp.1713-1738, 2011.
DOI : 10.1056/NEJMra1102942

URL : https://hal.archives-ouvertes.fr/hal-01707812

G. Vernier-massouille, M. Balde, J. Salleron, D. Turck, J. Dupas et al., Natural History of Pediatric Crohn's Disease: A Population-Based Cohort Study, Gastroenterology, vol.135, issue.4, pp.1106-1119, 2008.
DOI : 10.1053/j.gastro.2008.06.079

F. Rieder, E. Zimmermann, F. Remzi, and W. Sandborn, Crohn's disease complicated by strictures: a systematic review, Gut, vol.3, issue.Suppl. 8, pp.1072-84, 2013.
DOI : 10.1016/j.crohns.2009.06.001

K. Thia, W. Sandborn, W. Harmsen, A. Zinsmeister, E. Loftus et al., Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort, Gastroenterology, vol.139, issue.4, pp.1147-55, 2010.
DOI : 10.1053/j.gastro.2010.06.070

E. Domènech, M. Mañosa, and E. Cabré, An Overview of the Natural History of Inflammatory Bowel Diseases, Digestive Diseases, vol.32, issue.4, pp.320-327, 2014.
DOI : 10.1159/000358131

D. Seah, D. Cruz, and P. , Review article: the practical management of acute severe ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.25, issue.6 Suppl., pp.482-513, 2016.
DOI : 10.1159/000170882

G. Bouguen and L. Peyrin-biroulet, Surgery for adult Crohn's disease: what is the actual risk?, Gut, vol.60, issue.9, pp.1178-81, 2011.
DOI : 10.1136/gut.2010.234617

J. Askling, A. Ekbom, and O. Olén, Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study, Aliment Pharmacol Ther, p.2017

C. Eriksson, Y. Cao, S. Rundquist, Y. Zhulina, I. Henriksson et al., Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in ??rebro, Sweden, 1963-2010, Alimentary Pharmacology & Therapeutics, vol.7, issue.8, pp.748-757, 1963.
DOI : 10.2214/ajr.117.2.292

V. Billioud, W. Sandborn, and L. Peyrin-biroulet, Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review, The American Journal of Gastroenterology, vol.104, issue.4, pp.674-84, 2011.
DOI : 10.1038/ajg.2008.38

S. Ben-horin and Y. Chowers, Review article: loss of response to anti-TNF treatments in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.58, issue.9, pp.987-95, 2011.
DOI : 10.1136/gut.2008.157339

H. Herfarth, G. Rogler, and P. Higgins, Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol, Feb, vol.13, issue.2, pp.336-344, 2015.

D. Gibson, Z. Heetun, C. Redmond, K. Nanda, D. Keegan et al., An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.13, issue.2
DOI : 10.1016/j.cgh.2014.07.041

D. 'haens, B. G. Feagan, and &. V. Jairath, Review article: dose optimisation of infliximab for acute severe ulcerative colitis, Aliment Pharmacol Ther, vol.45, issue.5, pp.617-630, 2017.

S. Lichtiger and D. Present, Preliminary report: cyclosporin in treatment of severe active ulcerative colitis, The Lancet, vol.336, issue.8706, 1990.
DOI : 10.1016/0140-6736(90)91521-B

R. Harvey and J. Bradshaw, A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY, The Lancet, vol.315, issue.8167, p.514, 1980.
DOI : 10.1016/S0140-6736(80)92767-1

F. Magro, P. Gionchetti, R. Eliakim, S. Ardizzone, A. Armuzzi et al., Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders, Journal of Crohn's and Colitis, vol.124, issue.76, pp.649-670, 2017.
DOI : 10.1016/S0016-5085(03)00171-9

L. Biroulet, G. Cullen, M. Daperno, T. Kucharzik, F. Rieder et al., 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management, J Crohns Colitis, vol.11, issue.1, pp.20173-20198

J. Satsangi, M. Silverberg, S. Vermeire, and J. Colombel, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.
DOI : 10.1136/gut.2005.082909

C. Seow, A. Newman, S. Irwin, A. Steinhart, M. Silverberg et al., Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis, Gut, vol.59, issue.01, pp.49-54, 2010.
DOI : 10.1136/gut.2009.183095

J. Brandse, G. Van-den-brink, M. Wildenberg, D. Van-der-kleij, T. Rispens et al., Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis, Gastroenterology, vol.149, issue.2, pp.350-355, 2015.
DOI : 10.1053/j.gastro.2015.04.016

E. Stange and . European, Crohn's and Colitis Organisation (ECCO) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis, J Crohns Colitis. Feb, vol.4, issue.1, pp.7-27, 2010.

N. Vande-casteele, H. Herfarth, J. Katz, Y. Falck-ytter, and S. Singh, American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases, Gastroenterology, vol.153, issue.3, pp.835-857, 2017.
DOI : 10.1053/j.gastro.2017.07.031

J. Vandenbroucke, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies Ann Intern Med, pp.573-577, 2007.

N. Breslow, Analysis of Survival Data under the Proportional Hazards Model, International Statistical Review / Revue Internationale de Statistique, vol.43, issue.1, pp.1-45, 1975.
DOI : 10.2307/1402659

R. Cox, Regression Models and Life-Tables, Journal of the Royal Statistical Society. Series B (Methodological), vol.34, pp.2-187, 1972.
DOI : 10.1007/978-1-4612-4380-9_37

D. Hosmer and S. Lemeshow, Applied logistic regression, Wiley Series in Probability and Mathematical Statistics, 2000.
DOI : 10.1002/0471722146

J. Burke, Y. Velupillai, O. Connell, P. Coffey, and J. , National trends in intestinal resection for Crohn???s disease in the post-biologic era, International Journal of Colorectal Disease, vol.99, issue.5, 2013.
DOI : 10.1002/bjs.8698

M. Lazarev, T. Ullman, W. Schraut, K. Kip, M. Saul et al., Small bowel resection rates in Crohn??s disease and the indication for surgery over time: Experience from a large tertiary care center, Inflammatory Bowel Diseases, vol.136, issue.5, pp.830-835, 2010.
DOI : 10.1053/j.gastro.2008.10.051

R. Lynch, D. Lowe, A. Protheroe, R. Driscoll, J. Rhodes et al., Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit, Alimentary Pharmacology & Therapeutics, vol.60, issue.Suppl. 2, pp.935-980, 2013.
DOI : 10.1136/gut.2010.216895

M. Allez, K. Karmiris, E. Louis, G. Van-assche, S. Ben-horin et al., Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects, Journal of Crohn's and Colitis, vol.31, issue.36, pp.355-66, 2010.
DOI : 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W

N. Ding, A. Hart, D. Cruz, and P. , Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management, Alimentary Pharmacology & Therapeutics, vol.104, issue.Suppl. 1, pp.30-51, 2016.
DOI : 10.1038/ajg.2009.372

I. Digestives, Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, Lancet, vol.380, issue.9857, pp.1909-1924, 2012.

A. Seagrove, M. Alam, L. Alrubaiy, W. Cheung, C. Clement et al., Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT), BMJ Open, vol.4, issue.4, p.5091, 2014.
DOI : 10.1136/bmjopen-2014-005091

M. Flamant, S. Paul, and X. Roblin, Golimumab for the treatment of ulcerative colitis, Expert Opinion on Biological Therapy, vol.56, issue.2, pp.879-886
DOI : 10.1111/j.1365-2036.2009.04027.x

L. Gibiansky and E. Gibiansky, Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic???pharmacodynamic modeling of biologics, Expert Opinion on Drug Metabolism & Toxicology, vol.52, issue.7, pp.803-815, 2009.
DOI : 10.1208/aapsj0902020

P. Biancheri, R. Brezski, D. Sabatino, A. Greenplate, A. Soring et al., Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease, Gastroenterology, vol.149, issue.6, pp.1564-1574, 2015.
DOI : 10.1053/j.gastro.2015.07.002

F. Baert, V. Kondragunta, S. Lockton, V. Casteele, N. Hauenstein et al., Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial, Gut, vol.10, issue.(Suppl 1), pp.1126-1157, 2016.
DOI : 10.1016/j.cgh.2012.06.032

B. Sands, F. Anderson, C. Bernstein, W. Chey, B. Feagan et al., Infliximab Maintenance Therapy for Fistulizing Crohn's Disease, New England Journal of Medicine, vol.350, issue.9, pp.876-85, 2004.
DOI : 10.1056/NEJMoa030815

P. Rutgeerts, W. Sandborn, B. Feagan, W. Reinisch, A. Olson et al., Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-76, 2005.
DOI : 10.1056/NEJMoa050516

M. Choy, D. Seah, and A. Gorelik, Mo1878 Comparison of Accelerated Infliximab Induction vs Standard Induction Treatment in Acute Severe Ulcerative Colitis, Gastroenterology, vol.150, issue.4, pp.803-843, 2016.
DOI : 10.1016/S0016-5085(16)32720-2

I. Dotan, R. Y. Yanai, H. Becker, S. Fishman, S. Yahav et al., Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.12, pp.2247-59, 2014.
DOI : 10.1016/j.cgh.2012.06.032

I. Solberg, I. Lygren, J. Jahnsen, E. Aadland, O. Høie et al., Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study), Scandinavian Journal of Gastroenterology, vol.19, issue.2, pp.431-471, 2009.
DOI : 10.3109/00365529609004876

O. Bernell, A. Lapidus, and G. Hellers, Risk Factors for Surgery and Postoperative Recurrence in Crohn???s Disease, Annals of Surgery, vol.231, issue.1, pp.38-45, 2000.
DOI : 10.1097/00000658-200001000-00006

M. Arias, V. Casteele, N. Vermeire, S. De-buck-van-overstraeten, A. Billiet et al., A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.13, issue.3, pp.531-539, 2015.
DOI : 10.1016/j.cgh.2014.07.055

W. Sandborn, P. Rutgeerts, B. Feagan, W. Reinisch, A. Olson et al., Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab, Gastroenterology, vol.137, issue.4, pp.1250-60, 2009.
DOI : 10.1053/j.gastro.2009.06.061

J. Feuerstein, G. Nguyen, S. Kupfer, Y. Falck-ytter, and S. Singh, American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease, Gastroenterology, vol.153, issue.3, pp.827-834, 2017.
DOI : 10.1053/j.gastro.2017.07.032

A. Yarur, M. Kubiliun, F. Czul, D. Sussman, M. Quintero et al., Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy, Clinical Gastroenterology and Hepatology, vol.13, issue.6, pp.1118-1142
DOI : 10.1016/j.cgh.2014.12.026

A. Yarur, V. Kanagala, D. Stein, F. Czul, M. Quintero et al., 514 Higher Infliximab Trough Levels Are Associated With a Higher Rate of Perianal Fistula Healing in Patients With Crohn's Disease, Gastroenterology, vol.150, issue.4, 2017.
DOI : 10.1016/S0016-5085(16)30460-7

B. Ungar, Y. Mazor, R. Weisshof, H. Yanai, R. Y. Goren et al., Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.11, issue.12, pp.1293-1302, 2016.
DOI : 10.1016/j.cgh.2012.10.020

G. Blackhouse, N. Assasi, F. Xie, J. Marshall, E. Irvine et al., Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-?? drugs for refractory Crohn's disease, Journal of Crohn's and Colitis, vol.30, issue.3, pp.77-85, 2012.
DOI : 10.1111/j.1365-2036.2009.04033.x

C. Steenholdt, J. Brynskov, O. Thomsen, L. Munck, J. Fallingborg et al., Individualised therapy is more cost-effective than dose intensification in patients with Crohn???s disease who lose response to anti-TNF treatment: a randomised, controlled trial, Gut, vol.356, issue.Suppl 1, pp.919-946, 2014.
DOI : 10.1016/S0140-6736(00)02871-3

A. Yarur, A. Jain, D. Sussman, J. Barkin, M. Quintero et al., The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study, Gut, vol.46, issue.(Suppl 6), pp.249-55, 2016.
DOI : 10.1016/j.cyto.2009.02.001

O. Nielsen, Y. Li, B. Johansson-lindbom, and M. Coskun, Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease, Trends in Molecular Medicine, vol.23, issue.4, pp.362-374
DOI : 10.1016/j.molmed.2017.02.002

S. Danese, M. Grisham, J. Hodge, and J. Telliez, JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines, American Journal of Physiology-Gastrointestinal and Liver Physiology, vol.67, issue.3, pp.155-62
DOI : 10.3748/wjg.v20.i1.91

D. Vries, L. Wildenberg, M. , D. Jonge, W. et al., The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease, Journal of Crohn's and Colitis, vol.374, issue.7, pp.885-893, 2017.
DOI : 10.1056/NEJMoa1513248

G. Lichtenstein, B. Feagan, R. Cohen, B. Salzberg, R. Diamond et al., Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT??? Registry, The American Journal of Gastroenterology, vol.31, issue.9, pp.1409-1431, 2012.
DOI : 10.3899/jrheum.100347

S. Hendler, B. Cohen, J. Colombel, B. Sands, L. Mayer et al., High-Dose Infliximab Therapy in Crohn's Disease: Clinical Experience, Safety, and Efficacy, Journal of Crohn's and Colitis, vol.109, issue.11, pp.266-75
DOI : 10.1038/ajg.2014.146

C. Gasche, J. Scholmerich, J. Brynskov, D. Haens, G. Hanauer et al., A Simple Classification of Crohn??s Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998, Inflammatory Bowel Diseases, vol.111, issue.1, pp.8-15, 1998.
DOI : 10.1053/gast.1996.v111.pm8780560

J. Cosnes, S. Cattan, A. Blain, L. Beaugerie, F. Carbonnel et al., Longterm evolution of disease behavior of Crohn's disease, Inflamm Bowel Dis, 2002.

K. Schroeder, W. Tremaine, and D. Ilstrup, Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis, New England Journal of Medicine, vol.317, issue.26, pp.1625-1634, 1987.
DOI : 10.1056/NEJM198712243172603

S. Truelove and L. Witts, Cortisone in Ulcerative Colitis, BMJ, vol.2, issue.4947, pp.1041-1048, 1955.
DOI : 10.1136/bmj.2.4947.1041

S. Travis, D. Schnell, P. Krzeski, M. Abreu, D. Altman et al., Developing an instrument to 42

L. Vuitton, L. Peyrin-biroulet, J. Colombel, B. Pariente, P. De-chambrun et al., Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus, Alimentary Pharmacology & Therapeutics, vol.12, issue.6, pp.801-813, 2017.
DOI : 10.1016/j.cgh.2013.07.022

L. Vuitton, P. Marteau, W. Sandborn, B. Levesque, B. Feagan et al., IOIBD technical review on endoscopic indices for Crohn's disease clinical trials, Gut, vol.59, issue.(Suppl), pp.1447-55, 2016.
DOI : 10.1136/gut.2009.194159